表紙
市場調査レポート

Edgemont Pharmaceuticals, LLC:製品パイプライン分析

Edgemont Pharmaceuticals, LLC - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 293968
出版日 ページ情報 英文 17 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
Edgemont Pharmaceuticals, LLC:製品パイプライン分析 Edgemont Pharmaceuticals, LLC - Product Pipeline Review - 2014
出版日: 2014年06月15日 ページ情報: 英文 17 Pages
概要

当レポートでは、Edgemont Pharmaceuticals, LLCにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Edgemont Pharmaceuticals, LLCの基本情報

Edgemont Pharmaceuticals, LLCの概要

  • 主要情報
  • 企業情報

Edgemont Pharmaceuticals, LLC:R&Dの概要

  • 主な治療範囲

Edgemont Pharmaceuticals, LLC:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Edgemont Pharmaceuticals, LLC:パイプライン製品の概況

Edgemont Pharmaceuticals, LLC:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Edgemont Pharmaceuticals, LLC:薬剤プロファイル

  • EDG-004
  • EDG-005
  • EDG-006
  • EDG-007
  • EDG-008

Edgemont Pharmaceuticals, LLC:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC05010CDB

Global Markets Direct's, 'Edgemont Pharmaceuticals, LLC - Product Pipeline Review - 2014', provides an overview of the Edgemont Pharmaceuticals, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Edgemont Pharmaceuticals, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Edgemont Pharmaceuticals, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Edgemont Pharmaceuticals, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Edgemont Pharmaceuticals, LLC's pipeline products

Reasons to buy

  • Evaluate Edgemont Pharmaceuticals, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Edgemont Pharmaceuticals, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Edgemont Pharmaceuticals, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Edgemont Pharmaceuticals, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Edgemont Pharmaceuticals, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Edgemont Pharmaceuticals, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Edgemont Pharmaceuticals, LLC Snapshot
    • Edgemont Pharmaceuticals, LLC Overview
    • Key Information
    • Key Facts
  • Edgemont Pharmaceuticals, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Edgemont Pharmaceuticals, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Edgemont Pharmaceuticals, LLC - Pipeline Products Glance
    • Edgemont Pharmaceuticals, LLC - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Edgemont Pharmaceuticals, LLC - Drug Profiles
    • EDG-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EDG-005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EDG-006
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EDG-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EDG-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Edgemont Pharmaceuticals, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Edgemont Pharmaceuticals, LLC, Key Information
  • Edgemont Pharmaceuticals, LLC, Key Facts
  • Edgemont Pharmaceuticals, LLC - Pipeline by Indication, 2014
  • Edgemont Pharmaceuticals, LLC - Pipeline by Stage of Development, 2014
  • Edgemont Pharmaceuticals, LLC - Monotherapy Products in Pipeline, 2014
  • Edgemont Pharmaceuticals, LLC - Unknown, 2014

List of Figures

  • Edgemont Pharmaceuticals, LLC - Pipeline by Top 10 Indication, 2014
Back to Top